[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584728":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":40,"collaborators":10,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":53,"minAge":54,"maxAge":10,"enrollmentInfo":55,"targetDuration":10,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Peking University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Preoperative drug therapy combined with R0 resection in patients with gastric cancer",null,"Names: MRD testing Description: MRD refers to the small, residual number of cancer cells that remain in a patient's body after treatment, often undetectable by conventional methods, but detectable using ctDNA. MRD-positive indicates the presence of residual disease, while MRD-negative suggests potential cure.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Ziyu Li, MD.,PhD","CONTACT","0086-10-88121122","ziyu_li@hsc.pku.edu.cn",[19],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Peking University Cancer Hospital & Institute","RECRUITING","Beijing","Beijing Municipality","100142","China","CN",{"type":28,"coordinates":29},"Point",[30,31],116.39723,39.9075,{"lat":31,"lon":30},[34,37],{"name":35,"role":15,"phone":16,"phoneExt":10,"email":36},"Yongning Jia Associate Chief Physician, Dr.","yongningjia@bjmu.edu.cn",{"name":38,"role":15,"phone":16,"phoneExt":10,"email":39},"Honglin Zhu, Dr.","honglinzhu@hsc.pku.edu.cn",{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":20,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Ziyu Li, MD","Chief Physician","100584728","ctdna-mrd-monitoring-after-resection-in-gastric-cancer-100584728",false,"NCT06893133","ctDNA-MRD Monitoring After Resection in Gastric Cancer","Personalized ctDNA-MRD in Recurrence Monitoring for Gastric Cancer Patients Undergoing Perioperative Treatment Combined With Curative Surgical Resection","MRD-GC","Inclusion Criteria:\n\n1. Patients have received neoadjuvant therapy and radical resection (R0).\n2. Pathologically confirmed ypTNM stage II-III gastric or gastroesophageal junction adenocarcinoma.\n3. Patients must be able to provide sufficient fresh tissue\u002Fbiopsies or minimum 5-10 FFPE sections for NGS-WES analysis.\n4. Patients must be able to follow the study visit schedule and be willing to cooperate with the study by providing blood samples at the indicated time point.\n\nExclusion Criteria:\n\n1. Patients who could not receive enhanced CT, gastroscopy and other routine review after surgery.\n2. Patients who could not perform WES or ctDNA-MRD detection for various reasons after surgery.\n3. Other cases considered unsuitable for inclusion by researchers.",true,"ALL","18 Years",{"count":56,"type":57},110,"ESTIMATED","OBSERVATIONAL","Numerous studies have demonstrated that circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection has significant clinical value in postoperative recurrence monitoring, adjuvant treatment decision-making, and early intervention. Our previous retrospective study, using fixed ctDNA-MRD, confirmed that postoperative ctDNA-MRD can predict recurrence risk. Therefore, we plan to conduct a further prospective, multicenter, observational study, utilizing a combination of personalized ctDNA-MRD and fixed MRD panels, to dynamically monitor gastric cancer patients who have received neoadjuvant therapy followed by curative resection. The study will systematically analyze the correlation between ctDNA-MRD status and tumor recurrence and metastasis, assess its sensitivity and specificity in recurrence prediction, and compare its early warning advantage over traditional imaging techniques in predicting recurrence.",[61],"Gastric Cancer",[63,64,61],"ctDNA","MRD","2026-04-19",{"date":67,"type":68},"2026-04-21","ACTUAL",{"date":70,"type":68},"2025-04-08",{"date":72,"type":57},"2027-04-30",{"name":5,"class":6},1]